Startup profile for Curie.Bio: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.
Venture Capital Tracker logo
Venture Capital Tracker

Startup profile · funding coverage

Curie.Bio funding, valuation and investors

Biotech VC/accelerator pairing $5–15M seed checks with embedded drug-discovery services.

Keep track of Curie.Bio

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Launch

$520M · 2022

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$520M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

Stage not recorded · Boston, Massachusetts

Investors in latest funding

Other: ARCH Venture Partners , Andreessen Horowitz

Latest tracked event: Fund add-on (January 2025). It is shown separately because it is not counted as disclosed equity funding.

Sources: latest funding Last verified: 2026-07-25

Overview

Curie.Bio is a hybrid biotech venture firm and accelerator investing $5–15M seed checks in pre–Series A therapeutics startups while providing embedded drug-discovery services. Launched in 2022 with $520M backed by ARCH, GV, and a16z; added $340M in January 2025. It is a fund/platform, not a traditional operating company.

Why Curie.Bio is interesting

Curie.Bio is itself a fund/platform — a16z and ARCH co-back the vehicle that writes seed checks and runs vendor-heavy R&D ops for founders.

Product & use cases

Combines venture capital with operational drug-discovery services — portfolio companies get capital plus CRO/lab management.

  • Seed funding for first-time biotech founders
  • Outsourced CRO and lab ops
  • Accelerating IND-enabling studies

Key facts

  • Launch (2022): $520M; ARCH, GV, a16z (Fierce Biotech)
  • Jan 2025: +$340M for 15–25 startups/year (STAT)

Funding history (newest first)

Fund add-on

2025-01 $340M

Source: https://www.statnews.com/2025/01/curie-bio-fund/

Launch

2022 $520M

Source: https://www.fiercebiotech.com/biotech/curie-bio-launches-520m

Investors in our directory

Funds linked from Curie.Bio's profile — open a fund page for stage focus and related deal articles.

Andreessen Horowitz ARCH Venture Partners

Competitive landscape

Edge: Services + capital model reduces operational burden on first-time biotech CEOs.

Operational support is rare at seed stage. Returns depend on portfolio biotech outcomes.

  • Flagship Pioneering adjacent

    Company-creation at larger scale.

  • Third Rock Ventures adjacent

    Therapeutics VC with company-building.

  • IndieBio adjacent

    Life-sciences accelerator.

  • Traditional biotech VC incumbent

    Capital only.

Notable stories

  • Curie was founded to solve the first-time biotech CEO problem — CRO management alongside capital (Fierce Biotech, 2022).

Industries

Biotech & Life Sciences Healthtech

FAQs about Curie.Bio

Practical answers founders, operators, and investors typically search for.

Biotech VC/accelerator with $5–15M seed checks and embedded drug-discovery services.
No — it's a venture fund and services platform.
ARCH (/fund/arch-venture-partners) and a16z (/fund/andreessen-horowitz).
$5–15M seed checks.
Adds operational CRO/lab services beyond capital.
2022 with $520M; +$340M in 2025.
Boston, Massachusetts.
Yes — via curie.bio.
Pre–Series A therapeutics across modalities.
Fund/platform — not a startup stage.
Website All startups Funding news

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.